Physician profile
Caroline Hebert
NPI 1023620259
$8,283.53
in general payments reported to CMS, 2019-2025
46 companies · $2,920 in 2025
The $2,920 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,665 · 2022: $1,099 · 2023: $1,326 · 2024: $1,273 · 2025: $2,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,425 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,425.11 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,118.94 | 2021-2025 | Farxiga, Breztri |
| Abbvie INC. | $1,078.61 | 2021-2025 | |
| Amgen INC. | $922.50 | 2021-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $497.03 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $426.32 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Kowa Pharmaceuticals America, INC. | $372.98 | 2021-2024 | Livalo, Seglentis |
| Vanda Pharmaceuticals INC. | $302.11 | 2025 | Fanapt |
| Corium, LLC | $300.84 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $288.24 | 2021-2025 | Trintellix |
| Esperion Therapeutics, INC. | $255.22 | 2021-2025 | Nexletol |
| Pfizer INC. | $239.87 | 2024-2025 | |
| Madrigal Pharmaceuticals | $231.70 | 2025 | Rezdiffra |
| Otsuka America Pharmaceutical, INC. | $167.56 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $164.67 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $157.88 | 2022-2025 | Auvelity |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.